mRNA transcript diversity creates new opportunities for pharmacological intervention.

Area of Science:

• Molecular Biology
• Genetics
• Pharmacology

Background:

• Most protein-coding genes produce multiple RNA transcripts via alternative splicing and other mechanisms.
• These alternative transcripts, though often overlooked in drug design, can possess distinct functions and regulatory roles.
• Transcriptional variations are tissue-specific and influenced by genetic and environmental factors, impacting disease risk.

Purpose of the Study:

• To highlight the significance of RNA transcript diversity in physiological processes and disease.
• To explore the therapeutic potential of targeting alternative RNA transcripts for precision medicine.
• To emphasize the need to integrate transcript diversity into drug design and development strategies.

Main Methods:

• Review of current literature on alternative splicing, RNA editing, and variable UTRs.
• Analysis of high-throughput sequencing technologies for transcript discovery.
• Examination of emerging therapeutic strategies, including splice-site-directed oligonucleotides.

Main Results:

• Alternative transcripts can encode proteins with unique functions, offering targeted therapeutic opportunities.
• Genetic variations and environmental factors influence transcript profiles, contributing to disease.
• Novel RNA transcripts and protein isoforms are being discovered, expanding therapeutic targets.
• Oligonucleotide-based therapies targeting aberrant splicing are in clinical trials for genetic disorders.

Conclusions:

• Considering gene transcript diversity is crucial for developing effective, targeted therapies with reduced adverse effects.
• Targeting specific RNA transcripts presents a promising approach for personalized medicine and treating complex diseases.
• Advancements in sequencing technologies are accelerating the discovery and therapeutic application of transcript diversity.